Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting Merck, known as MSD outside of the United States and Canada, announced today that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting. [News Source]